Allspring Global Investments
LCTX icon

Allspring Global Investments’s Lineage Cell Therapeutics LCTX Stock Holding History

Allspring Global Investments’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-170,379
Closed -$262K – 2821
2022
Q1 		$262K Sell
170,379
-352,534
-67% -$547K ﹤0.01% 2481
2021
Q4 		$1.28M Buy
+522,913
New +$1.22M ﹤0.01% 1790

Other funds holding LCTX

BC
Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
RA
Raffles Associates New York $117M AUM 22.1% 1-Year Est. Return
PGP
Prescott General Partners Boca Raton, Florida $1.96B AUM 58.65% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Allspring Global Investments's LCTX Position: Q2 2022 in Review

Allspring Global Investments sold out of Lineage Cell Therapeutics (LCTX) in Q2 2022, closing a stake of 170,379 shares — an estimated $262K sold.

Allspring Global Investments first reported a position in LCTX in Q4 2021 and held it in 2 quarters. The position peaked at $1.28M in Q4 2021. 101 funds tracked by Wall St. Rank hold LCTX as of Q2 2022.

  • Allspring Global Investments reported no remaining Lineage Cell Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Allspring Global Investments sold 170,379 Lineage Cell Therapeutics shares in Q2 2022, an estimated $262K.
  • Allspring Global Investments first reported a position in Lineage Cell Therapeutics in Q4 2021 and held it in 2 quarters.
  • Allspring Global Investments's Lineage Cell Therapeutics position peaked at $1.28M in Q4 2021.
  • 101 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q2 2022.

Based on Allspring Global Investments's 13F filing for Q2 2022, filed 25 Jul 2022.